Approved indications: Megatope is approved for intravenous use in adults to determine total blood and plasma volumes as part of diagnostic blood volume studies.

Off-label uses: Other potential applications of iodinated I-131 albumin (such as certain hemodynamic or protein turnover studies) have been described historically, but these uses are uncommon today and would be considered off-label for Megatope, with evidence largely from older, small clinical studies.

Efficacy expectations:

• After injection, Megatope distributes through the bloodstream within minutes, and timed blood samples taken over the next hour or so allow accurate calculation of blood and plasma volume.
• When protocols are followed, test accuracy is high and comparable to other I-131–albumin tracers used for blood volume measurement.
• Overall reliability depends more on proper technique (dose calibration, sample timing, and lab counting methods) than on the specific brand of albumin tracer.

Typical dosing: For adult blood or plasma volume studies, Megatope is given intravenously in very small radioactive activities, usually about 0.185–1.85 MBq (5–50 microcuries), with total activity generally limited to no more than 7.4 MBq (200 microcuries) in any one week.

How it is given:

• Administered only by trained personnel in a licensed nuclear medicine or radiology facility, typically through a vein in the arm.
• The exact activity is measured in a dose calibrator immediately before injection, and a shielded syringe is used to protect staff from unnecessary radiation.
• Patients are often given strong iodine drops (such as Lugol’s solution) before and for a short time after the study to block uptake of iodine-131 by the thyroid.

Special instructions:

• Follow any pre-test directions carefully, including instructions about iodine drops, fasting (if required), and timing of other scans or thyroid medications.
• Remain available for all required post-injection blood sampling, since accurate timing of samples is essential for reliable blood volume calculations.

Missed dose and overdose:

• If you miss or must change your appointment, contact the imaging center to reschedule; Megatope is not self-administered at home.
• Overdose is rare and would be managed by the specialist team, which may include additional thyroid-blocking iodine, radiation-dose assessment, and monitoring for allergic or systemic reactions.

Common side effects: Most people have no noticeable side effects; some may experience mild injection-site discomfort, flushing, or a brief feeling of warmth when the tracer is injected.

Serious or rare adverse effects: Rarely, serious allergic reactions (difficulty breathing or swallowing, rash, itching, facial or throat swelling, fast heartbeat) or fever/pyrogenic reactions can occur and require immediate medical attention; aseptic meningitis has been reported when similar products were used in the fluid around the brain, a use for which Megatope is not approved.

Warnings and precautions:

• Megatope contains radioactive iodine-131, so it is used only when the expected diagnostic benefit justifies radiation exposure, and doses are kept as low as reasonably achievable.
• Pregnancy: iodine-131 crosses the placenta and can permanently affect the fetal thyroid; use in pregnant patients is generally avoided unless clearly needed and then only with appropriate thyroid-blocking measures and specialist supervision.
• Breastfeeding: iodine-131 passes into breast milk and can affect the infant’s thyroid, so breastfeeding is typically stopped during treatment and for a prolonged period afterward until radioactivity has decayed.
• Pediatrics: safety and effectiveness in children have not been established, and other methods are usually preferred.
• Kidney or liver disease and severe systemic illness may alter handling of the tracer or tolerance of the procedure and require individualized risk–benefit assessment.

Comparative safety: At the very low activities used for blood volume determination, overall radiation dose and risk of serious reactions are low and similar to other diagnostic radiopharmaceuticals, though all such agents carry some radiation and allergy risk.

Reporting side effects and safety updates: Side effects should be reported promptly to the nuclear medicine team and may also be reported directly to the FDA’s MedWatch program (online or by calling 1-800-FDA-1088); current safety information is available in the prescribing information and on FDA drug safety pages.

Drug and supplement interactions:

• No specific clinically important drug–drug interactions are well documented for Megatope, but iodine-containing medicines, iodinated contrast media, and thyroid drugs can alter iodine handling and may change thyroid exposure or test interpretation.
• Inform your care team about all prescription and nonprescription medicines, vitamins, herbal products, and recent contrast-enhanced imaging studies before the test.
• Alcohol has no known direct interaction with Megatope but may be discouraged around the time of testing depending on your overall health.

Food and diagnostic procedure interactions:

• Routine meals usually do not interfere, but very high iodine intake (for example from certain supplements or seaweed/kelp products) can affect thyroid iodine kinetics and should be discussed beforehand.
• Other nuclear medicine scans or radioiodine therapies may need to be timed and coordinated to avoid overlapping tracers and to limit cumulative radiation exposure.

Precautions and monitoring:

• Use is generally restricted to adults for whom accurate blood or plasma volume information is clinically important.
• Pregnant or breastfeeding patients, and those with severe kidney impairment or major uncontrolled illnesses, require careful individualized risk–benefit consideration.
• During and after the study, clinical status and blood samples are monitored as needed, and in patients undergoing repeated studies, clinicians may track cumulative radiation dose and thyroid function over time.

Q: What is Megatope and why is it used?
A: Megatope is a human albumin protein labeled with a tiny amount of radioactive iodine-131 and is used in adults to measure total blood and plasma volumes during specialized diagnostic tests.

Q: Will I be radioactive after the injection, and is it safe to be around others?
A: You will carry a very small amount of radioactivity for a short time, but at the low activities used for blood volume studies it is generally safe to be around other people, with your care team advising if any special precautions are needed.

Q: How should I prepare for a Megatope blood volume test?
A: Follow the instructions from your nuclear medicine team, which may include taking iodine drops on a specific schedule, adjusting certain thyroid medicines, and arriving in time to stay for post-injection blood sampling.

Q: Can I have a Megatope study if I am pregnant or breastfeeding?
A: Because Megatope contains iodine-131, it is usually avoided during pregnancy and breastfeeding unless there is a compelling medical need, in which case specialists will discuss the risks, use thyroid-blocking strategies, and may recommend interrupting breastfeeding for a prolonged period.

Q: How long does Megatope stay in my body?
A: The radioactive iodine in Megatope has a physical half-life of about eight days and is gradually eliminated mainly in the urine, but the radiation dose from the small diagnostic activity used is low and your team will keep total exposure as limited as reasonably possible.